Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

What you should know about prophylaxis and treatment of radiographic and magnetic resonance contrast medium extravasation.

Hrycyk J, Heverhagen JT, Boehm I.

Acta Radiol. 2018 Jan 1:284185118782000. doi: 10.1177/0284185118782000. [Epub ahead of print]

PMID:
29896979
2.

Delayed reaction following gadolinium-based contrast agent application.

Boehm I, Heverhagen JT.

Magn Reson Imaging. 2018 Jul;50:10-11. doi: 10.1016/j.mri.2018.03.007. Epub 2018 Mar 11.

PMID:
29540332
3.

The real-life costs of emotion regulation in anorexia nervosa: a combined ecological momentary assessment and fMRI study.

Seidel M, King JA, Ritschel F, Boehm I, Geisler D, Bernardoni F, Holzapfel L, Diestel S, Diers K, Strobel A, Goschke T, Walter H, Roessner V, Ehrlich S.

Transl Psychiatry. 2018 Jan 24;8(1):28. doi: 10.1038/s41398-017-0004-7.

4.

Processing and regulation of negative emotions in anorexia nervosa: An fMRI study.

Seidel M, King JA, Ritschel F, Boehm I, Geisler D, Bernardoni F, Beck M, Pauligk S, Biemann R, Strobel A, Goschke T, Walter H, Roessner V, Ehrlich S.

Neuroimage Clin. 2017 Dec 24;18:1-8. doi: 10.1016/j.nicl.2017.12.035. eCollection 2018.

5.

Insight into the dynamic of gadolinium based contrast agent (GBCA) hypersensitivity: Acquisition, persistence and disappearance.

Boehm I, Hungerb├╝hler M, Heverhagen JT.

Magn Reson Imaging. 2018 Jun;49:1-3. doi: 10.1016/j.mri.2017.12.013. Epub 2017 Dec 13.

PMID:
29247752
6.

Radiological visibility of an immediate contrast medium side-effect.

Boehm I.

Eur J Radiol. 2018 Jan;98:226-227. doi: 10.1016/j.ejrad.2017.11.006. Epub 2017 Nov 14. No abstract available.

PMID:
29183641
7.

The Trajectory of Anhedonic and Depressive Symptoms in Anorexia Nervosa: A Longitudinal and Cross-Sectional Approach.

Boehm I, Flohr L, Steding J, Holzapfel L, Seitz J, Roessner V, Ehrlich S.

Eur Eat Disord Rev. 2018 Jan;26(1):69-74. doi: 10.1002/erv.2565. Epub 2017 Nov 23.

PMID:
29168305
8.

Gadolinium depositions after the application of the hepatospecific gadolinium-based contrast agent gadoxetate disodium.

Kim SY, Maurer MH, Richter JK, Heverhagen JT, Boehm IB.

Eur J Intern Med. 2018 Jan;47:e9-e11. doi: 10.1016/j.ejim.2017.09.033. Epub 2017 Sep 29. No abstract available.

PMID:
28965739
9.

General anaesthesia for patients with a history of a contrast medium-induced anaphylaxis: a useful prophylaxis?

Boehm I, Nairz K, Morelli J, Silva Hasembank Keller P, Heverhagen JT.

Br J Radiol. 2017 Nov;90(1079):20160647. doi: 10.1259/bjr.20160647. Epub 2017 Sep 6. Review.

10.

Subliminal and supraliminal processing of reward-related stimuli in anorexia nervosa.

Boehm I, King JA, Bernardoni F, Geisler D, Seidel M, Ritschel F, Goschke T, Haynes JD, Roessner V, Ehrlich S.

Psychol Med. 2018 Apr;48(5):790-800. doi: 10.1017/S0033291717002161. Epub 2017 Aug 23.

PMID:
28832300
11.

Neural correlates of altered feedback learning in women recovered from anorexia nervosa.

Ritschel F, Geisler D, King JA, Bernardoni F, Seidel M, Boehm I, Vettermann R, Biemann R, Roessner V, Smolka MN, Ehrlich S.

Sci Rep. 2017 Jul 14;7(1):5421. doi: 10.1038/s41598-017-04761-y.

12.

Risks of contrast media applied via the gastrointestinal route.

Boehm I, Morelli J, Nairz K, Silva Hasembank Keller P, Heverhagen JT.

Eur J Intern Med. 2017 Jul;42:e19-e21. doi: 10.1016/j.ejim.2017.04.005. Epub 2017 Apr 14. No abstract available.

PMID:
28416378
13.

Increased anterior cingulate cortex response precedes behavioural adaptation in anorexia nervosa.

Geisler D, Ritschel F, King JA, Bernardoni F, Seidel M, Boehm I, Runge F, Goschke T, Roessner V, Smolka MN, Ehrlich S.

Sci Rep. 2017 Feb 13;7:42066. doi: 10.1038/srep42066.

14.

A naturalistic examination of negative affect and disorder-related rumination in anorexia nervosa.

Seidel M, Petermann J, Diestel S, Ritschel F, Boehm I, King JA, Geisler D, Bernardoni F, Roessner V, Goschke T, Ehrlich S.

Eur Child Adolesc Psychiatry. 2016 Nov;25(11):1207-1216. Epub 2016 Mar 31.

PMID:
27033353
15.

Partially restored resting-state functional connectivity in women recovered from anorexia nervosa.

Boehm I, Geisler D, Tam F, King JA, Ritschel F, Seidel M, Bernardoni F, Murr J, Goschke T, Calhoun VD, Roessner V, Ehrlich S.

J Psychiatry Neurosci. 2016 Oct;41(6):377-385.

16.

Beta blockers and intravenous roentgen contrast materials: Which risks do exist?

Boehm I, Morelli J, Nairz K, Silva Hasembank Keller P, Heverhagen JT.

Eur J Intern Med. 2016 Nov;35:e17-e18. doi: 10.1016/j.ejim.2016.08.003. Epub 2016 Aug 13. Review. No abstract available.

PMID:
27531627
17.

Effects of perceptual body image distortion and early weight gain on long-term outcome of adolescent anorexia nervosa.

Boehm I, Finke B, Tam FI, Fittig E, Scholz M, Gantchev K, Roessner V, Ehrlich S.

Eur Child Adolesc Psychiatry. 2016 Dec;25(12):1319-1326. Epub 2016 May 7.

PMID:
27154049
18.

Weight restoration therapy rapidly reverses cortical thinning in anorexia nervosa: A longitudinal study.

Bernardoni F, King JA, Geisler D, Stein E, Jaite C, N├Ątsch D, Tam FI, Boehm I, Seidel M, Roessner V, Ehrlich S.

Neuroimage. 2016 Apr 15;130:214-222. doi: 10.1016/j.neuroimage.2016.02.003. Epub 2016 Feb 11.

PMID:
26876474
19.

Abnormal functional global and local brain connectivity in female patients with anorexia nervosa.

Geisler D, Borchardt V, Lord AR, Boehm I, Ritschel F, Zwipp J, Clas S, King JA, Wolff-Stephan S, Roessner V, Walter M, Ehrlich S.

J Psychiatry Neurosci. 2016 Jan;41(1):6-15.

20.

Elevated cognitive control over reward processing in recovered female patients with anorexia nervosa.

Ehrlich S, Geisler D, Ritschel F, King JA, Seidel M, Boehm I, Breier M, Clas S, Weiss J, Marxen M, Smolka MN, Roessner V, Kroemer NB.

J Psychiatry Neurosci. 2015 Sep;40(5):307-15.

21.

Reduced functional connectivity in the thalamo-insular subnetwork in patients with acute anorexia nervosa.

Ehrlich S, Lord AR, Geisler D, Borchardt V, Boehm I, Seidel M, Ritschel F, Schulze A, King JA, Weidner K, Roessner V, Walter M.

Hum Brain Mapp. 2015 May;36(5):1772-81. doi: 10.1002/hbm.22736. Epub 2015 Jan 22.

PMID:
25611053
22.

Temporal delay discounting in acutely ill and weight-recovered patients with anorexia nervosa.

Ritschel F, King JA, Geisler D, Flohr L, Neidel F, Boehm I, Seidel M, Zwipp J, Ripke S, Smolka MN, Roessner V, Ehrlich S.

Psychol Med. 2015 Apr;45(6):1229-39. doi: 10.1017/S0033291714002311. Epub 2015 Jan 12.

PMID:
25579471
23.

Global cortical thinning in acute anorexia nervosa normalizes following long-term weight restoration.

King JA, Geisler D, Ritschel F, Boehm I, Seidel M, Roschinski B, Soltwedel L, Zwipp J, Pfuhl G, Marxen M, Roessner V, Ehrlich S.

Biol Psychiatry. 2015 Apr 1;77(7):624-32. doi: 10.1016/j.biopsych.2014.09.005. Epub 2014 Sep 22.

PMID:
25433902
24.

Increased resting state functional connectivity in the fronto-parietal and default mode network in anorexia nervosa.

Boehm I, Geisler D, King JA, Ritschel F, Seidel M, Deza Araujo Y, Petermann J, Lohmeier H, Weiss J, Walter M, Roessner V, Ehrlich S.

Front Behav Neurosci. 2014 Oct 2;8:346. doi: 10.3389/fnbeh.2014.00346. eCollection 2014.

25.

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, Smith MA, Lock RB.

Pediatr Blood Cancer. 2015 Jan;62(1):65-71. doi: 10.1002/pbc.25133. Epub 2014 Sep 9.

26.

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.

Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2014 Sep 1;20(17):4520-31. doi: 10.1158/1078-0432.CCR-14-0259. Epub 2014 Jul 10.

27.

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RB.

Clin Cancer Res. 2013 Apr 1;19(7):1795-805. doi: 10.1158/1078-0432.CCR-12-3613. Epub 2013 Feb 20. Erratum in: Clin Cancer Res. 2013 Jun 1;19(11):3108.

28.

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H, Boehm I, Groepper D, Reynolds CP, Stewart CF, Lock RB.

PLoS One. 2012;7(3):e33894. doi: 10.1371/journal.pone.0033894. Epub 2012 Mar 29.

29.

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M.

PLoS One. 2011;6(8):e23108. doi: 10.1371/journal.pone.0023108. Epub 2011 Aug 11.

30.

Adverse reactions during gadoteridol-enhanced MR imaging.

Boehm IB.

Radiology. 2011 Sep;260(3):915-6; author reply 916. doi: 10.1148/radiol.11110689. No abstract available.

PMID:
21846765
31.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1291-304. doi: 10.1007/s00280-011-1618-8. Epub 2011 Mar 30.

32.

Iodinated contrast agents are not forbidden in patients with iodine allergy.

Boehm I.

Cardiovasc Intervent Radiol. 2010 Apr;33(2):435-6; author reply 437. doi: 10.1007/s00270-010-9799-9. No abstract available.

PMID:
20087736
33.

Heterosubtypic anti-avian H5N1 influenza antibodies in intravenous immunoglobulins from globally separate populations protect against H5N1 infection in cell culture.

Sullivan JS, Selleck PW, Downton T, Boehm I, Axell AM, Ayob Y, Kapitza NM, Dyer W, Fitzgerald A, Walsh B, Lynch GW.

J Mol Genet Med. 2009 Dec 23;3(2):217-24.

34.

MPIOs and cellular MRI: the greater the particles, the better?

Boehm I.

J Neurotrauma. 2010 May;27(5):973. doi: 10.1089/neu.2009.1192. No abstract available.

PMID:
19929168
35.

Application route of iodinated contrast media as a risk factor for adverse reactions.

Boehm I.

Gastrointest Endosc. 2009 Sep;70(3):602; author reply 602. doi: 10.1016/j.gie.2009.01.034. No abstract available.

PMID:
19699989
36.

Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS.

Boehm I.

Clin Rheumatol. 2009 Nov;28(11):1347-8. doi: 10.1007/s10067-009-1257-1. Epub 2009 Aug 20.

PMID:
19693642
37.

Is interleukin-2 therapy still a risk factor for adverse reactions in concert with iodinated contrast medium injection?

Boehm I.

Acta Radiol. 2009 Sep;50(7):752-3. doi: 10.1080/02841850903061452. No abstract available.

PMID:
19629773
38.

Which laboratory parameters are characteristic for nephrogenic systemic fibrosis?

Boehm I.

Nephrol Dial Transplant. 2009 Jul;24(7):2293; author reply 2293-4. doi: 10.1093/ndt/gfp147. Epub 2009 Apr 8. No abstract available.

PMID:
19357110
39.

Contrast medium and patients at risk: asthma.

Boehm I.

Acta Radiol. 2009 Apr;50(3):348. doi: 10.1080/02841850902729885. No abstract available.

PMID:
19234895
40.

Testing the parents to confirm genotypes of CF patients is highly recommended: report of two cases.

Stuhrmann M, Brakensiek K, Argyriou L, Boehm I, Hinderhofer K, Bauer I, Rhode BM, Maelzer M, Zuehlke C, Krueger G, Schmidtke J.

Eur J Hum Genet. 2009 Apr;17(4):417-9. doi: 10.1038/ejhg.2008.190. Epub 2008 Dec 3. No abstract available.

41.

Does chemical structure of Gd-containing contrast agents contribute to mortality in nephrogenic systemic fibrosis?

Boehm IB.

Kidney Int. 2008 Dec;74(12):1627. doi: 10.1038/ki.2008.527. No abstract available.

42.

Polyarteritis nodosa mimicking peripheral vascular disease.

Boehm I.

J Gen Intern Med. 2008 Dec;23(12):2157-8. doi: 10.1007/s11606-008-0795-6. No abstract available.

43.

Seafood allergy and radiocontrast media: are physicians propagating a myth?

Boehm I.

Am J Med. 2008 Aug;121(8):e19. doi: 10.1016/j.amjmed.2008.03.035. No abstract available.

PMID:
18691465
44.

Nephrogenic systemic fibrosis in patients undergoing hemodialysis: comment on the article by Todd et al.

Boehm I.

Arthritis Rheum. 2008 Mar;58(3):910; author reply 910-1. doi: 10.1002/art.23293. No abstract available.

45.

High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.

Yuan FF, Boehm I, Chan PK, Marks K, Tang JW, Hui DS, Sung JJ, Dyer WB, Geczy AF, Sullivan JS.

Clin Vaccine Immunol. 2007 Dec;14(12):1644-5. Epub 2007 Oct 3.

46.

Apoptosis in physiological and pathological skin: implications for therapy.

Boehm I.

Curr Mol Med. 2006 Jun;6(4):375-94. Review.

PMID:
16900661
47.

The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK.

Barr RK, Boehm I, Attwood PV, Watt PM, Bogoyevitch MA.

J Biol Chem. 2004 Aug 27;279(35):36327-38. Epub 2004 Jun 18.

48.

Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101. Review.

PMID:
15023353
49.

Rapid detection of vanA and vanB genes directly from clinical specimens and enrichment broths by real-time multiplex PCR assay.

Palladino S, Kay ID, Flexman JP, Boehm I, Costa AM, Lambert EJ, Christiansen KJ.

J Clin Microbiol. 2003 Jun;41(6):2483-6.

Supplemental Content

Support Center